Vico Medical Honored as One of CCI's 'Top 10 Most Promising Enterprises' at Its 10th Anniversary Gala

September 13,2025 Oriental Medical Device Innovation Conference and the 10th Anniversary Celebration of the Chinese Cardiovascular Physician Innovation Club (CCI)The conference was held in grand style. The venue was filled with luminaries, gathering innovative elites from the medical, industrial, and investment sectors to jointly witness the magnificent epic and new beginning of China's cardiovascular medical device innovation over the past decade. During the highly anticipated award ceremony,Wuhan Vickor Medical Technology Co., Ltd. Honored with CCI 10th Anniversary "Top Ten Potential Enterprises" Award.This honor fully recognizes the company's continuous efforts in the field of cardiovascular intervention, significant technological innovation achievements, and steady corporate growth, clearly demonstrating the promising future and enormous development potential of this emerging force in the industry.

China Cardiovascular Innovation Club (CCI), founded byProf. Ge Junbo, Academician of the Chinese Academy of Sciences, Director of the Cardiology Department at Zhongshan Hospital Affiliated to Fudan University, and President of CCI Innovation AcademyFounded in 2015 by a group of top experts in the cardiovascular field. The club adheres to the innovative concept of "From the doctors, by the engineers, for the patients, empowered by investors & entrepreneurs," and has consistently dedicated itself for a decade to building an open innovation ecosystem that integrates innovative training, design exchange, research support, and industry collaboration. CCI serves as a clinically driven innovation bridge, playing three key roles: connecting clinics with enterprises, bridging policies with practices, and integrating domestic and international efforts.

Since its establishment, Vickor has been committed to breakthroughs in core technologies in the field of cardiovascular disease treatment.

In the field of heart failure prevention and treatment, the atrial shunt device independently developed by the company has demonstrated excellent efficacy in optimizing hemodynamic parameters in heart failure patients and significantly improving cardiac function. For the prevention of cardioembolic stroke, the patent foramen ovale (PFO) closure device, with its innovative structural design, effectively enhances closure outcomes and surgical safety. In the treatment of valvular diseases, the transcatheter aortic valve replacement system addresses aortic regurgitation and aortic stenosis more efficiently without the need for pacing or general anesthesia, providing doctors with an optimal minimally invasive treatment option that tangibly improves patients' quality of life and long-term prognosis.

At the same time, Vickor actively promotes the deep integration of industry, academia, and research, proactively participates in CCI platform activities, and closely collaborates with clinical experts and engineers to quickly feedback real-world clinical needs into the product design and iteration process. ThisThe innovative mechanism centered on "the combination of medical and engineering" is not only an important path for the successful advancement of CCI but also injects continuous innovative vitality into Vickor Medical.

Awarded as "Top Ten Potential Enterprises," for Vickor, it is a milestone and, more importantly, a new starting point. This signifies that the company's innovative direction, technical accumulation, and development prospects have been highly recognized by China's top innovation platforms and expert panels.

"A Decade of Sharpening the Sword, Brings the Fragrance of Plum Blossoms. CCI has written a magnificent epic of innovation in China's medical device industry over the past ten years. Vickor, as a rising force in this innovative forest, has been honored as one of the 'Top Ten Potential Enterprises,' a strong testament to its innovative strength and promising future. Standing at the starting point of CCI’s new decade, Wuhan Vickor Medical Technology Co., Ltd. will adhere to its original aspiration, continue to take meeting clinical needs as its mission, and be driven by technological innovation, empowered by the CCI platform."Join hands with Chinese cardiovascular innovators, set off from the "heart," move towards the "new," and jointly write the next glorious decade of China's medical device innovation!